home / stock / ckdxf / ckdxf quote
Last: | $0.29 |
---|---|
Change Percent: | 0.0% |
Open: | $0.29 |
Close: | $0.29 |
High: | $0.29 |
Low: | $0.29 |
Volume: | 130 |
Last Trade Date Time: | 11/14/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.29 | $0.29 | $0.29 | $0.29 | $0.29 | 130 | 11-14-2023 |
$0.42 | $0.41 | $0.42 | $0.42 | $0.41 | 30,000 | 06-01-2023 |
$0.82 | $0 | $0.82 | $0 | $0 | 6 | 03-06-2023 |
$0.82 | $0.82 | $0.82 | $0.82 | $0.82 | 5,000 | 01-24-2022 |
$1.09 | $1.09 | $1.09 | $1.09 | $1.09 | 3,400 | 04-26-2021 |
$1.2 | $1.2 | $1.2 | $1.2 | $1.2 | 2,000 | 02-25-2021 |
$1.52 | $1.52 | $1.52 | $1.52 | $1.52 | 5,000 | 01-21-2021 |
$1.38 | $1.38 | $1.38 | $1.38 | $1.38 | 1,000 | 12-30-2020 |
$1.6 | $1.6 | $1.6 | $1.6 | $1.6 | 23,800 | 06-29-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 02-12-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 02-11-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 02-10-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 02-07-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 02-06-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 02-05-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 02-04-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 02-03-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 01-31-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 01-30-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 01-29-2020 |
News, Short Squeeze, Breakout and More Instantly...
MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, incl...
New Shares under the Retail Entitlement Offer and New Options under the Placement and Entitlement Offer expected to commence normal trading on Thursday, 18 July 2024 Retail Entitlement Offer follows successful Institutional Entitlement Offer and institutional Placement raising approxima...
Research underpins sozinibercept’s potential as novel, first-in-class VEGF-C/D ‘trap’ to prevent blood vessel growth and vascular leakage in the retina Published in peer-reviewed journal Ophthalmology and Therapy MELBOURNE, Australia and PRINCETON, N.J....